{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:59:17Z","timestamp":1785113957153,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54350-1","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:04:15Z","timestamp":1779386655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenomic landscape of a Moroccan cohort: enhancing global diversity and addressing the North African gap"],"prefix":"10.1038","volume":"16","author":[{"given":"Souad","family":"Kartti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Walid","family":"Chemao-Elfihri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Hakmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marouane","family":"Aherkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"ElJaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahcen","family":"Balouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmostafa El","family":"Fahime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahcen","family":"Belyamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber","family":"Boutayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"1","key":"54350_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/age.13376","volume":"55","author":"A Vaidhya","year":"2024","unstructured":"Vaidhya, A. et al. Relevance of pharmacogenetics and pharmacogenomics in veterinary clinical practice: A review. Anim. Genet. 55(1), 3\u201319 (2024).","journal-title":"Anim. Genet."},{"issue":"2","key":"54350_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.53346\/wjapmr.2024.7.2.0049","volume":"7","author":"A Banji","year":"2024","unstructured":"Banji, A., Adekola, A. & Dada, S. A. Pharmacogenomic approaches for tailoring medication to genetic profiles in diverse populations. World J. Adv. Pharm. Med. Res. 7(2), 109\u2013118 (2024).","journal-title":"World J. Adv. Pharm. Med. Res."},{"issue":"1","key":"54350_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","volume":"177","author":"G Sirugo","year":"2019","unstructured":"Sirugo, G., Williams, S. M. & Tishkoff, S. A. The missing diversity in human genetic studies. Cell 177(1), 26\u201331 (2019).","journal-title":"Cell"},{"issue":"7624","key":"54350_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/538161a","volume":"538","author":"AB Popejoy","year":"2016","unstructured":"Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. Nature 538(7624), 161\u2013164 (2016).","journal-title":"Nature"},{"issue":"S7","key":"54350_CR5","first-page":"9","volume":"7","author":"NGS Al-Amri","year":"2024","unstructured":"Al-Amri, N. G. S. et al. An overview of genetic biomarkers influencing drug response and efficacy in specific populations. J. Int. Crisis Risk Commun. Res. 7(S7), 9 (2024).","journal-title":"J. Int. Crisis Risk Commun. Res."},{"issue":"9","key":"54350_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162866","volume":"11","author":"C Mizzi","year":"2016","unstructured":"Mizzi, C. et al. A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics. PLoS ONE 11(9), e0162866 (2016).","journal-title":"PLoS ONE"},{"key":"54350_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1180640","volume":"14","author":"SR Samarasinghe","year":"2023","unstructured":"Samarasinghe, S. R. et al. The pharmacogenomic landscape of an Indigenous Australian population. Front. Pharmacol. 14, 1180640 (2023).","journal-title":"Front. Pharmacol."},{"key":"54350_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1553536","volume":"16","author":"M Jelovac","year":"2025","unstructured":"Jelovac, M. et al. Comprehensive pharmacogenomics profiling of the Serbian population. Front. Pharmacol. 16, 1553536 (2025).","journal-title":"Front. Pharmacol."},{"key":"54350_CR9","doi-asserted-by":"publisher","DOI":"10.1017\/pcm.2025.2","volume":"3","author":"D Velayutham","year":"2025","unstructured":"Velayutham, D. et al. Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: A population-based cohort study. Camb. Prisms Precis. Med. 3, e4 (2025).","journal-title":"Camb. Prisms Precis. Med."},{"issue":"3","key":"54350_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1871","volume":"10","author":"S Mestiri","year":"2022","unstructured":"Mestiri, S. et al. New insight into the human genetic diversity in North African populations by genotyping of SNPs in DRD3, CSMD1 and NRG1 genes. Mol. Genet. Genomic Med. 10(3), e1871 (2022).","journal-title":"Mol. Genet. Genomic Med."},{"key":"54350_CR11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-121323-104008","author":"D Twesigomwe","year":"2025","unstructured":"Twesigomwe, D. et al. Pharmacogenomics in Africa: A potential catalyst for precision medicine in genetically diverse populations. Annu. Rev. Genomics Hum. Genet. https:\/\/doi.org\/10.1146\/annurev-genom-121323-104008 (2025).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"1","key":"54350_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s42003-025-08020-z","volume":"8","author":"E El Fahime","year":"2025","unstructured":"El Fahime, E. et al. Moroccan genome project: Genomic insight into a North African population. Commun. Biol. 8(1), 584 (2025).","journal-title":"Commun. Biol."},{"key":"54350_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1380613","volume":"15","author":"H Jmel","year":"2024","unstructured":"Jmel, H. et al. Pharmacogenetic landscape of pain management variants among Mediterranean populations. Front. Pharmacol. 15, 1380613 (2024).","journal-title":"Front. Pharmacol."},{"key":"54350_CR14","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S390092","author":"I Mouhrach","year":"2023","unstructured":"Mouhrach, I. et al. Influence of CYP450 enzymes and ABCB1 polymorphisms on clopidogrel response in Moroccan patients with acute coronary syndromes. Pharmacogenomics Pers. Med. https:\/\/doi.org\/10.2147\/PGPM.S390092 (2023).","journal-title":"Pharmacogenomics Pers. Med."},{"key":"54350_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2023.107045","volume":"249","author":"I Belbacha","year":"2024","unstructured":"Belbacha, I. et al. The APOBEC3G gene rs2294367 (C> G) variant is associated with HIV-1 infection in Moroccan subjects. Acta Trop. 249, 107045 (2024).","journal-title":"Acta Trop."},{"key":"54350_CR16","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv [q-bio. GN]. (2013)."},{"key":"54350_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1201\/9781003354062-4","volume-title":"Next-generation sequencing","author":"V Snijesh","year":"2025","unstructured":"Snijesh, V., Shivakumar, K., Punya, K. & Murthy, A. S. N. Best practices for variant calling using the genome analysis toolkit. In Next-generation sequencing 60\u201379 (CRC Press, 2025)."},{"issue":"2","key":"54350_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10(2), giab008 (2021).","journal-title":"GigaScience"},{"key":"54350_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13742-015-0047-8","author":"CC Chang","year":"2015","unstructured":"Chang, C. C. et al. Second-generation PLINK: Rising to the challenge of larger and richer datasets. GigaScience https:\/\/doi.org\/10.1186\/s13742-015-0047-8 (2015).","journal-title":"GigaScience"},{"issue":"D1","key":"54350_CR20","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","volume":"52","author":"B Zdrazil","year":"2024","unstructured":"Zdrazil, B. et al. The ChEMBL database in 2023: A drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 52(D1), D1180\u2013D1192 (2024).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"54350_CR21","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox, C. et al. DrugBank 6.0: The DrugBank knowledgebase for 2024. Nucleic Acids Res. 52(D1), D1265\u2013D1275 (2024).","journal-title":"Nucleic Acids Res."},{"key":"54350_CR22","doi-asserted-by":"crossref","unstructured":"Whirl-Carrillo, M., Huddart, R. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. 110(3):563-72 (2021).","DOI":"10.1002\/cpt.2350"},{"issue":"D1","key":"54350_CR23","doi-asserted-by":"publisher","first-page":"D1143","DOI":"10.1093\/nar\/gkad989","volume":"52","author":"M Schubach","year":"2024","unstructured":"Schubach, M., Maass, T., Nazaretyan, L., R\u00f6ner, S. & Kircher, M. CADD v1. 7: Using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions. Nucleic Acids Res. 52(D1), D1143\u2013D1154 (2024).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"54350_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41397-018-0044-2","volume":"19","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y., Mkrtchian, S., Kumondai, M., Hiratsuka, M. & Lauschke, V. M. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 19(2), 115\u2013126 (2019).","journal-title":"Pharmacogenomics J."},{"issue":"7","key":"54350_CR25","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41588-023-01415-w","volume":"55","author":"RJ Hofmeister","year":"2023","unstructured":"Hofmeister, R. J., Ribeiro, D. M., Rubinacci, S. & Delaneau, O. Accurate rare variant phasing of whole-genome and whole-exome sequencing data in the UK Biobank. Nat. Genet. 55(7), 1243\u20131249 (2023).","journal-title":"Nat. Genet."},{"issue":"7","key":"54350_CR26","doi-asserted-by":"publisher","first-page":"e0272129","DOI":"10.1371\/journal.pone.0272129","volume":"17","author":"SB Lee","year":"2022","unstructured":"Lee, S. B., Shin, J. Y., Kwon, N. J., Kim, C. & Seo, J. S. ClinPharmSeq: A targeted sequencing panel for clinical pharmacogenetics implementation. PLoS ONE 17(7), e0272129 (2022).","journal-title":"PLoS ONE"},{"issue":"6","key":"54350_CR27","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/cpt.1552","volume":"106","author":"SB Lee","year":"2019","unstructured":"Lee, S. B. & Wheeler, M. M. Calling star alleles with stargazer in 28 pharmacogenes with whole genome sequences. Clin. Pharmacol. Therapeutics. 106(6), 1328\u20131337 (2019).","journal-title":"Clin. Pharmacol. Therapeutics."},{"issue":"1","key":"54350_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1101\/gr.277075.122","volume":"33","author":"A Hari","year":"2023","unstructured":"Hari, A. et al. An efficient genotyper and star-allele caller for pharmacogenomics. Genome Res. 33(1), 61\u201370 (2023).","journal-title":"Genome Res."},{"issue":"10","key":"54350_CR29","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ajhg.2023.09.001","volume":"110","author":"B Li","year":"2023","unstructured":"Li, B. et al. Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank. Am. J. Human Genet. 110(10), 1628\u20131647 (2023).","journal-title":"Am. J. Human Genet."},{"issue":"1","key":"54350_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70065","volume":"13","author":"A Halman","year":"2025","unstructured":"Halman, A. & Conyers, R. BCyrius: An upgraded version of Cyrius for accurate CYP2D6 genotyping from short-read sequencing data. Pharmacol. Res. Perspect. 13(1), e70065 (2025).","journal-title":"Pharmacol. Res. Perspect."},{"issue":"8","key":"54350_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37(8), 907\u2013915 (2019).","journal-title":"Nat. Biotechnol."},{"issue":"30","key":"54350_CR32","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1073\/pnas.1707945114","volume":"114","author":"C Xie","year":"2017","unstructured":"Xie, C. et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proceed. Nat. Academy Sci. 114(30), 8059\u20138064 (2017).","journal-title":"Proceed. Nat. Academy Sci."},{"issue":"23","key":"54350_CR33","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek, A. et al. OptiType: Precision HLA typing from next-generation sequencing data. Bioinformatics 30(23), 3310\u20133316 (2014).","journal-title":"Bioinformatics"},{"issue":"21","key":"54350_CR34","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","volume":"31","author":"MJ Machiela","year":"2015","unstructured":"Machiela, M. J. & Chanock, S. J. LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31(21), 3555\u20133557 (2015).","journal-title":"Bioinformatics"},{"key":"54350_CR35","unstructured":"RCoreTeam. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. (2020)."},{"key":"54350_CR36","unstructured":"Van Rossum G DJF. Python reference manual. Centrum voor Wiskunde en Informatica Amsterdam. (1995)."},{"issue":"1","key":"54350_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/cpt.1409","volume":"106","author":"JT Brown","year":"2019","unstructured":"Brown, J. T. et al. Clinical pharmacogenetics implementation consortium guideline for Cytochrome P450 (CYP)2D6 genotype and Atomoxetine therapy. Clin. Pharmacol. Ther. 106(1), 94\u2013102 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"54350_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cpt.598","volume":"102","author":"GC Bell","year":"2017","unstructured":"Bell, G. C. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin. Pharmacol. Ther. 102(2), 213\u2013218 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"54350_CR39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpt.1007","volume":"103","author":"MP Goetz","year":"2018","unstructured":"Goetz, M. P. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin. Pharmacol. Ther. 103(5), 770\u2013777 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"54350_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"JK Hicks","year":"2017","unstructured":"Hicks, J. K. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. 102(1), 37\u201344 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"54350_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman, C. A. & Stevenson, J. M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin. Pharmacol. Ther. 114(1), 51\u201368 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"54350_CR42","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","volume":"110","author":"KR Crews","year":"2021","unstructured":"Crews, K. R. et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin. Pharmacol. Ther. 110(4), 888\u2013896 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"54350_CR43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee, C. R. et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and Clopidogrel therapy: 2022 update. Clin. Pharmacol. Ther. 112(5), 959\u2013967 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"54350_CR44","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cpt.2015","volume":"109","author":"JJ Lima","year":"2021","unstructured":"Lima, J. J. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin. Pharmacol. Ther. 109(6), 1417\u20131423 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"54350_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","volume":"102","author":"B Moriyama","year":"2017","unstructured":"Moriyama, B. et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin. Pharmacol. Ther. 102(1), 45\u201351 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"54350_CR46","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cpt.1477","volume":"106","author":"Z Desta","year":"2019","unstructured":"Desta, Z. et al. Clinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing antiretroviral therapy. Clin. Pharmacol. Ther. 106(4), 726\u2013733 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"54350_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cpt.1830","volume":"108","author":"KN Theken","year":"2020","unstructured":"Theken, K. N. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin. Pharmacol. Ther. 108(2), 191\u2013200 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"54350_CR48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cpt.2008","volume":"109","author":"JH Karnes","year":"2021","unstructured":"Karnes, J. H. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin. Pharmacol. Ther. 109(2), 302\u2013309 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"54350_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2019.03.032","volume":"140","author":"LA Johnson","year":"2019","unstructured":"Johnson, L. A. & Hug, L. A. Distribution of reactive oxygen species defense mechanisms across domain bacteria. Free Radical Biol. Med. 140, 93\u2013102 (2019).","journal-title":"Free Radical Biol. Med."},{"issue":"5","key":"54350_CR50","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff, R. M. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin. Pharmacol. Ther. 111(5), 1007\u20131021 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"54350_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell, K. A. et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther. 98(1), 19\u201324 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"54350_CR52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"JA Johnson","year":"2017","unstructured":"Johnson, J. A. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin. Pharmacol. Ther. 102(3), 397\u2013404 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"54350_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/clpt.2013.203","volume":"95","author":"AJ Muir","year":"2014","unstructured":"Muir, A. J. et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-\u03b1-based regimens. Clin. Pharmacol. Ther. 95(2), 141\u2013146 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"54350_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz, U. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin. Pharmacol. Ther. 103(2), 210\u2013216 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"54350_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.269","volume":"99","author":"R Gammal","year":"2016","unstructured":"Gammal, R. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin. Pharmacol. Ther. 99(4), 363\u2013369 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"54350_CR56","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cpt.1319","volume":"105","author":"SG Gonsalves","year":"2019","unstructured":"Gonsalves, S. G. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes. Clin. Pharmacol. Ther. 105(6), 1338\u20131344 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"54350_CR57","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling, M. V. & Schwab, M. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin. Pharmacol. Ther. 105(5), 1095\u20131105 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"54350_CR58","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/cpt.2735","volume":"113","author":"RS Gammal","year":"2023","unstructured":"Gammal, R. S. & Pirmohamed, M. Expanded clinical pharmacogenetics implementation consortium guideline for medication use in the context of G6PD genotype. Clin. Pharmacol. Ther. 113(5), 973\u2013985 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"54350_CR59","first-page":"487","volume":"17","author":"O Sibomana","year":"2024","unstructured":"Sibomana, O. Genetic diversity landscape in African population: A review of implications for personalized and precision medicine. Pharmacogenomics Pers. Med. 17, 487\u2013496 (2024).","journal-title":"Pharmacogenomics Pers. Med."},{"issue":"11","key":"54350_CR60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2217\/pgs.12.105","volume":"13","author":"Q Liu","year":"2012","unstructured":"Liu, Q., Jamba, M., Patrick, C. III., Padmanabhan, S. & Brennan, M. D. Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics 13(11), 1227\u20131237 (2012).","journal-title":"Pharmacogenomics"},{"issue":"1","key":"54350_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40246-024-00594-9","volume":"18","author":"E Goljan","year":"2024","unstructured":"Goljan, E. et al. Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population. Hum. Genomics 18(1), 30 (2024).","journal-title":"Hum. Genomics"},{"issue":"4","key":"54350_CR62","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/1479-7364-4-4-238","volume":"4","author":"SC Marques","year":"2010","unstructured":"Marques, S. C. & Ikediobi, O. N. The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions. Hum. Genomics 4(4), 238\u2013249 (2010).","journal-title":"Hum. Genomics"},{"key":"54350_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005548","author":"MR Schweiger","year":"2009","unstructured":"Schweiger, M. R. et al. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0005548 (2009).","journal-title":"PLoS ONE"},{"key":"54350_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1326776","volume":"15","author":"Q Shubbar","year":"2024","unstructured":"Shubbar, Q. et al. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Front. Pharmacol. 15, 1326776 (2024).","journal-title":"Front. Pharmacol."},{"issue":"12","key":"54350_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168732","volume":"11","author":"LA Bader","year":"2016","unstructured":"Bader, L. A. & Elewa, H. The impact of genetic and non-genetic factors on Warfarin dose prediction in MENA Region: A systematic review. PLoS ONE 11(12), e0168732 (2016).","journal-title":"PLoS ONE"},{"issue":"8","key":"54350_CR66","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2217\/pgs-2016-0023","volume":"17","author":"VM Lauschke","year":"2016","unstructured":"Lauschke, V. M. & Ingelman-Sundberg, M. Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics 17(8), 917\u2013924 (2016).","journal-title":"Pharmacogenomics"},{"key":"54350_CR67","doi-asserted-by":"publisher","first-page":"3186328","DOI":"10.1155\/2017\/3186328","volume":"2017","author":"WL Fan","year":"2017","unstructured":"Fan, W. L., Shiao, M. S., Hui, R. C. & Su, S. C. HLA association with drug-induced adverse reactions. J. Immunol. Res. 2017, 3186328 (2017).","journal-title":"J. Immunol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54350-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:02:49Z","timestamp":1785110569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54350-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54350"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54350-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23273"}}